Gynecologic and Obstetric Investigation
Original Article
Labor Induction with 25-μg Misoprostol Vaginal CapsulesSanto S.a · Lourenço R.b · Centeno M.a · Pargana L.a · Clode N.a · Ferreira H.a · da Graça L.M.aDepartments of aObstetrics, Gynecology and Reproductive Medicine, and bPharmacy, Hospital Santa Maria, Lisbon, Portugal
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: March 03, 2009
Accepted: June 22, 2009
Published online: September 30, 2009
Issue release date: November 2009
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 5
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Aim: To evaluate the success rate and the safety profile of labor induction with a new misoprostol formulation – vaginal capsules of 25 μg of misoprostol. Methods: Labor induction was performed in 250 singleton term pregnancies; 149 (59.6%) were nulliparous. Vaginal capsules of 25 μg of misoprostol were placed in the posterior vaginal fornix every 6 h. Success rate, contractility and fetal heart rate abnormalities and fetal outcomes were evaluated. Results: The success rate of labor induction was 97.6%. The average number of vaginal administrations was 1.5. The mean interval between induction and active labor was 10 h and 20 min and the average length of labor was 15 h and 35 min. The cesarean section rate was 18.8%. There were 15 cases of tachysystole, 3 cases of hypertonus and 1 case of hyperstimulation syndrome. There were no adverse neonatal outcomes. Conclusions: This study allowed to conclude that labor induction with vaginal capsules of 25 μg of misoprostol is associated with an excellent success rate and safety profile.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Wing DA, Rahall A, Jones MM, Goodwin TM, Paul RH: Misoprostol: an effective agent for cervical ripening and labor induction. Am J Obstet Gynecol 1995;172:1811–1816.
- Mundle WR, Young DC: Vaginal misoprostol for induction of labor: a randomized controlled trial. Obstet Gynecol 1996;88:521–525.
- Farah LA, Sanchez-Ramos L, Rosa C, et al: Randomized trial of two doses of prostaglandin E1 analog misoprostol for labor induction. Am J Obstet Gynecol 1997;177:364–371.
- Kramer RL, Gilson GJ, Morrison DS, Martin D, Gonzales JL, Qualls CR: A randomized trial of misoprostol and oxytocin for induction of labor: safety and efficacy. Obstet Gynecol 1997;89:387–391.
- Sanchez-Ramos L, Kaunitz AM, Delke I: Labor induction with 25 μg versus 50 μg intravaginal misoprostol: a systematic review. Obstet Gynecol 2002;99:145–151.
- Wing DA, Jones MM, Rahall A, Goodwin TM, Paul RH: A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labor induction. Am J Obstet Gynecol 1995;172:1804–1810.
-
Tang OS, Danielsson K, Ho PC: Misoprostol: pharmacokinetic profiles, effects on the uterus and side effects. Int J Gynecol Obstet 2007;99:160–167.
External Resources
-
Hofmeyr GJ, Gülmezoglu AM: Vaginal misoprostol for cervical ripening and induction of labor. Cochrane Database Syst Rev 2003;1:CD000941.
- Meydanli MM, Çaliskan E, Burak F, Narin MA, Atmaca R: Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol. Int J Gynecol Obstet 2003;81:249–255.
- McKenna DS, Ester JB, Proffitt M, Waddell K: Misoprostol outpatient cervical ripening without subsequent labor induction: a randomized trial. Obstet Gynecol 2004;104:579–584.
Article / Publication Details
Received: March 03, 2009
Accepted: June 22, 2009
Published online: September 30, 2009
Issue release date: November 2009
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 5
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
